Affimed to Present at the UBS Global Healthcare Conference -- New York
May 17, 2016 05:00 ET
|
Affimed NV
HEIDELBERG, Germany, May 17, 2016 (GLOBE NEWSWIRE) -- Affimed (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference –...
Affimed Reports Financial Results for Fourth Quarter and Year End 2015
March 30, 2016 07:30 ET
|
Affimed NV
HEIDELBERG, Germany, March 30, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed to Present at the Cowen and Company 36th Annual Health Care Conference
February 29, 2016 05:07 ET
|
Affimed NV
HEIDELBERG, Germany, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients with Hodgkin Lymphoma
January 25, 2016 05:00 ET
|
Affimed NV
HEIDELBERG, Germany, Jan. 25, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed to Present at the Oppenheimer 26th Annual Healthcare Conference -- New York
December 01, 2015 05:00 ET
|
Affimed NV
HEIDELBERG, Germany, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Oppenheimer 26th Annual Healthcare...
Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference -- London
November 11, 2015 05:00 ET
|
Affimed NV
HEIDELBERG, Germany, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Jefferies Autumn 2015 Global...
Affimed to Present Data on NK- and T-Cell Engagers at ASH
November 05, 2015 09:28 ET
|
Affimed NV
Heidelberg, Germany, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that...
Affimed Announces Significant Investment by an Existing Shareholder
October 14, 2015 16:07 ET
|
Affimed NV
HEIDELBERG, Germany, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that an...
Affimed Added to Russell 2000(R) Index
June 30, 2015 05:00 ET
|
Affimed NV
HEIDELBERG, Germany, June 30, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
AbCheck and Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership
June 17, 2015 05:04 ET
|
Affimed NV
HEIDELBERG, Germany, June 17, 2015 (GLOBE NEWSWIRE) -- AbCheck s.r.o, a wholly owned subsidiary of Affimed N.V., Heidelberg, Germany, and Pierre Fabre Pharmaceuticals announced today that they have...